The 10th Annual Immuno-Oncology Summit was held in Boston during October 12-14, 2022. Creative Biolabs, as an exhibitor, attended the 10th Annual Immuno-Oncology Summit at booth #9 and has attracted many attendeesRead More…
Single-cell Analysis Reveals Mechanism of Relapse of CD19-targeted CAR-T Therapy
Chimeric antigen receptor T-cell (CAR-T) immunotherapy targeting CD19 has achieved surprising results in the treatment of malignant hematological tumors such as relapsed/refractory acute lymphoblastic leukemia (ALL). Clinical trial data show that theRead More…
Synthetic IL-9 Receptor Enables T Cells to Fight Cancer without Chemotherapy or Radiation
Immunotherapy is currently a hot topic in the field of tumor treatment, and has shown excellent therapeutic effects in clinic. Among all kinds, adoptive T cell therapy is undoubtedly the most anticipated.Read More…
IFN-γ Receptor Signaling Pathway Enables CAR-T Cells to Efficiently Kill Solid Tumors
In a new study, researchers from Massachusetts General Hospital find that the interferon gamma receptor (IFNγR) signaling pathway is critical for glioblastoma susceptibility to CAR-T cell immunotherapy . The same phenomenon hasRead More…
CAR-T Cells Targeting CD123 Specifically Kill Acute Myeloid Leukemia Cells
In a new preclinical study, researchers from Weill Cornell Medicine found that genetically engineered T cells successfully targeted specific cancer cells that may lead to relapse in acute myeloid leukemia (AML), andRead More…
Research Advances in CAR-T Cell Therapy (as of May 2022)
CAR-T (chimeric-antigen receptor T-cell immunotherapy) has significant efficacy in the treatment of acute leukemia and non-Hodgkin’s lymphoma, and is considered to be one of the most promising tumor treatments. In recent years,Read More…
Effect of scFv Domain on the Function and Toxicity of CAR-T
The detection and destruction of cancer cells by immune cells is the basis of all modern immunotherapies, including cancer vaccines, checkpoint blocking, and adoptive immune cell therapy (ACT). To achieve the productionRead More…
Overview of Global Pipelines of Cell Therapy for Cancer
In this March, Bristol-Myers Squibb and Bluebird Bio announced that their CAR-T cell therapy idecabtagene vicleucel (Abecma) targeting B cell maturation antigen (BCMA) has been approved for the treatment of multiple myeloma,Read More…
Talking About the New Targets and Techniques of CAR-T Therapy
Adoptive immunotherapy is a transformational therapy in hematology. One of the most representative adoptive immunotherapies is chimeric antigen receptor (CAR) T cell therapy. It expresses and synthesizes CAR on T cells byRead More…
The Future of Regulatory T Cell (Treg) Therapy: CAR-Treg
Regulatory T cells (Tregs) is a small group of immune cells, which specifically inhibit excessive immune activation and maintain immune homeostasis. In the past two decades, the advances in genome editing andRead More…